Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: Participants will gain a deeper insight into the available evidence for the treatment of acne, learn more on optimizing acne treatment and will be able to treat acne patients in accordance with current EU guidelines.

Introduction: Acne is one of the most frequent skin diseases. Many treatment options are available for the treatment of acne. But which treatment is the best for which acne type? What are the current treatment recommendations? For how long should the treatments be given and what recommendations are reasonable?

Materials / method: The European Acne Guidelines are based on a systematic literature search and a structured consensus process (S3 Level).

Results: For comedonal acne, topical retinoids, azelaic acid or BPO are recommended. For mild to moderate papulopustular acne, fix combination treatments with adapalene and BPO or BPD and Clindamycin get the highest strength of recommendation. For severe papulopustular acne and conglabate acne, systemic isotretinoin received the highest strength of recommendation.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): The guidelines were funded through a grant from the European Dermatology Forum

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: European Dermatology Forum

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): Cutera, Sciton, Aerolase, Lumenis, Lutronic

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: Severe acne is common, results in challenging permanent scarring and can cause psychological distress. The use of conventional treatments can be limited in some patients due to contraindications, inefficacy, side-effects or patient’s personal convenience.

Introduction: C. Acnes is a Gram-positive bacterium involved in the pathogenesis of acne. It generates fewer porphyrines. As sunlight exposure, illumination with an appropriate light alone (LED or CW Lamp, IPL, PDL …) may trigger photodynamic reactions in the sebaceous glands and can improve acne: ‘’endogenous PDT ‘’. Prior application of a photosensitizer

Materials / method: Studies report significantly different parameters: wavelength, dose, number and intervals of sessions. They are so heterogeneous that it’s very difficult to make any analysis and synthesis (about 2/3 were industry-sponsored, with small samples, no control, no randomization, high risk of bias, short follow-up, adverse effects under-reported…).
In the last Cochrane Review on all light therapies and acne (Barbaric et al., 2016), red-light MAL-PDT is the only treatment with a low to moderate certainty for reduction (clinically insignificant)
Waiting for further RCT using standardized assessments

Results: Current trends and clinical recommendations in 2019 for moderate to severe resistant acne could be as follows:
. For anti-inflammatory efficacy (transient, painless and without adverse-effects): numerous biweekly or weekly sessions of endogenous PDT (LED alone, far less IPLs or PDL)
- Blue light with high irradiance (60-120J/cm² - 20 min.)
- Red light with high irradiance
- Blue and red light with high irradiance (alternated)
- +/- yellow, green, red and infra-red lights for for their anti-inflammatory and anti-scarring effects
- (daily application of very low irradiance 1 J/cm² with HUD)

Conclusion: For long-term efficacy (approx. 16 weeks) on inflammatory and non inflammatory lesions, ‘’conventional’’ 3h MAL or ALA with occlusion red LED PDT seems the most efficient but with severe pain, high costs, contraindication during pregnancy and with the most adverse effects (volcanic eruption, 1 week of downtime, prolonged erythema or postinflammatory hyperpigmentation depending on the phototype)
In-between all practionners can taylor the protocol to suit each well-informed and consenting patient or patient’s parents.
The future already knocks at our doors with HUD or daylight use and new PS

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability